BPC-157 vs TB-500: Healing Peptide Comparison
BPC-157 (Body Protection Compound) is a 15-amino acid gastric peptide that promotes healing through VEGF upregulation and growth factor modulation, with the strongest evidence for tendon, ligament, and GI repair. TB-500 is a synthetic fragment of Thymosin Beta-4 that promotes healing through actin regulation, cell migration, and systemic anti-inflammatory pathways. Both are widely used in tissue repair research and are frequently stacked together for complementary effects.
Side-by-Side Comparison
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Mechanism | VEGF, EGF, FGF upregulation; NO modulation; growth factor pathways | Actin polymerization regulation; cell migration; anti-inflammatory |
| Evidence Grade | A | B+ |
| Source | Gastric juice-derived pentadecapeptide (15 AA) | Synthetic fragment of Thymosin Beta-4 (43 AA) |
| Route | Subcutaneous (local or systemic) or oral | Subcutaneous (systemic) |
| Typical Dose | 250 - 500 mcg/day | 2 - 5 mg twice weekly |
| Half-Life | ~4 hours (stable variant longer) | ~4-6 hours |
| Cycle Length | 4 - 8 weeks | 4 - 8 weeks (loading + maintenance) |
| Best For | Tendon, ligament, gut, nerve healing | Systemic inflammation, muscle injury, cardiac repair |
| Oral Bioavailability | Yes (moderate, for GI targets) | No |
| FDA Status | Not FDA-approved; research compound | Not FDA-approved; research compound |
| PubMed Citations | 100+ studies | 50+ studies |
| Cost (research grade) | $ | $$ |
BPC-157: Pros & Cons
Advantages
- Strongest evidence base among healing peptides
- Excellent tendon, ligament, and gut healing data
- Oral bioavailability for GI tract targets
- Low cost and widely available at research grade
- Well-tolerated with minimal reported side effects
- Neuroprotective properties documented in animal studies
Considerations
- Most evidence is from animal studies, limited human data
- Short half-life requires daily administration
- Local injection may be needed for targeted healing
- No FDA approval or regulatory oversight
- Mechanism not fully characterized in humans
TB-500: Pros & Cons
Advantages
- Broad systemic anti-inflammatory effects
- Promotes cell migration to injury sites
- Strong evidence for cardiac tissue repair
- Less frequent dosing (2x per week vs daily)
- Supports wound healing and angiogenesis
Considerations
- Lower evidence grade than BPC-157 overall
- No oral bioavailability
- Higher cost per cycle than BPC-157
- Theoretical concern about tumor growth (unproven)
- Fewer tendon-specific studies
- Not FDA-approved; limited human clinical data
Which Is Right for Your Research?
Decision Guide
Choose BPC-157 if: Your research focuses on localized tendon, ligament, or joint healing, gastrointestinal repair (ulcers, IBD, leaky gut), or nerve regeneration. BPC-157 has the deepest evidence base, oral bioavailability for GI targets, and the lowest cost per cycle. It is the single most-studied healing peptide in preclinical literature.
Choose TB-500 if: Your research targets systemic inflammation, large-area tissue repair, cardiac injury, or muscle damage. TB-500's cell migration and anti-inflammatory properties make it well-suited for broad injury recovery where systemic distribution matters more than targeted delivery.
Stack both if: Comprehensive healing is the objective. The BPC-157 + TB-500 stack is the most popular healing combination in peptide research due to complementary mechanisms. BPC-157 drives local growth factor upregulation while TB-500 provides systemic anti-inflammatory and cell migration support.
Frequently Asked Questions
BPC-157 has stronger evidence specifically for tendon and ligament healing. Animal studies show BPC-157 accelerates Achilles tendon repair, MCL healing, and rotator cuff recovery through VEGF upregulation and growth factor modulation. TB-500 supports broader tissue repair through cell migration, but has fewer tendon-specific studies. Many researchers combine both for synergistic benefits.
Yes, BPC-157 and TB-500 are commonly stacked in research protocols. Their complementary mechanisms provide synergistic healing benefits. A typical stack uses BPC-157 at 250-500mcg daily and TB-500 at 2-5mg twice weekly, with BPC-157 often injected near the injury site and TB-500 administered subcutaneously elsewhere.
BPC-157 is a 15-amino acid gastric peptide that works through localized growth factor upregulation (VEGF, EGF, FGF) and nitric oxide modulation. TB-500 is a 43-amino acid Thymosin Beta-4 fragment that works through actin polymerization regulation and systemic anti-inflammatory pathways. BPC-157 is often injected locally near injuries, while TB-500 works systemically.
Related Protocol Guides
Verified Research Suppliers
Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards.
Related Tools & Resources

© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.